Ibnsina Pharma results, Q3 2023
Net profit, assets, equity and cash flow for Q3 2023, against the same period a year earlier, from the published financial statements.
Net profit42.03 millionEGP · +35.6% vs the same period a year earlier
Total assets18.68 billionEGP · +51.2% vs the same period a year earlier
Shareholders' equity1.41 billionEGP · +13.1% vs the same period a year earlier
Operating cash flow-310 millionEGP · −130.6% vs the same period a year earlier
In short
- Ibnsina Pharma's net profit for Q3 2023 was about 42.03 million EGP, up +35.6% from 30.99 million EGP in Q3 2022.
- Total assets at the end of Q3 2023 were about 18.68 billion EGP, and shareholders' equity about 1.41 billion EGP.
- Operating cash flow for Q3 2023 was negative at 310 million EGP.
Key lines against the same period a year earlier
This periodQ3 2022Change
Net profit42.03 million30.99 million+35.6%
Gross profit701 million371 million+89.0%
Total assets18.68 billion12.35 billion+51.2%
Total liabilities17.27 billion11.11 billion+55.5%
Shareholders' equity1.41 billion1.25 billion+13.1%
Total liabilities and equity18.68 billion12.35 billion+51.2%
Operating cash flow-310 million1.01 billion−130.6%
Investing cash flow-135 million-1.1 billion+87.8%
Financing cash flow480 million247 million+94.8%
Net change in cash35.88 million156 million−77.0%
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. Figures are as shown in the published statement summary; quarterly figures may be cumulative from the start of the fiscal year.
Ibnsina Pharma's Q3 2026 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy